{
  "drug_name": "Cefepime",
  "tradename": "Maxipime",
  "usage_and_dosing": {
    "general": [
      "Cefepime, FDA-approved in 1996, is a 4th generation cephalosporin with a structure that allows better and more rapid penetration through the cell wall of aerobic gram-negative bacilli.",
      "It is able to avoid destruction by some chromosomal beta-lactamases.",
      "Cefepime has in vitro activity against MSSA, Neisseria sp., H. influenzae and a broad range of gram-negative bacilli, including P. aeruginosa (Lancet Infect Dis 2007;7:338).",
      "An alternative antibiotic for drug resistant genotypes.",
      "Cefepime may be active vs. ESBL-producing aerobic gram-negative bacilli if administered in high doses: 2 gm IV q8h. However, the drug of choice for ESBL-producing Gram-negative bacilli is a carbapenem, not Cefepime.",
      "More active against Staph. aureus (MSSA) than 3rd generation cephalosporins."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV q8-12h",
      "other_dosing": "See Continuous, Extended Infusion Dosing"
    },
    "pediatric_dose": {
      "usual": "100 mg/kg/day (div q8h)",
      "pseudomonas": "150 mg/kg/day (div q8h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2",
    "half_life_esrd": "18",
    "dose_renal_function_normal": "2 gm IV q8h",
    "crcl_or_egfr": "CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h",
    "hemodialysis": {
        "fda_approved": "1 gm q24h (AD on dialysis days)",
        "alternative": "2 gm AD (3x/wk HD) 45"
    },
    "capd": "2 gm q48h",
    "crrt": "Dose per effluent rate, all modalities: 1 L/hr: 1 gm q8h, ≥2 L/hr: 1 gm q6h. EI, CVVH/CVVHD, UFR 30.1: 2 gm (over 4 hr) q8h 42, 43",
    "sled": "2 gm load, then 1 gm q6h OR 2 gm pre-, 3 gm post-SLED 49"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "Obesity: See Obesity Dosing Adjustments.",
    "ECMO: See ECMO Drug Dosing Adjustment."
  ],
  "adverse_effects": [
    "Hypersensitivity (rash)",
    "GI (nausea/vomiting, diarrhea, C. difficile infection)",
    "Local phlebitis",
    "Hematologic: Positive Coombs, neutropenia, eosinophilia, thrombocytopenia, increased INR.",
    "Cross-reactivity discussion: See Drug Allergy: Penicillins, Cephalosporins, Overview.",
    "Flushing reaction (similar to vancomycin histamine release syndrome) reported: Antimicrob Agents Chemother 2012;56:6387.",
    "Neurotoxicity:",
    "FDA safety warning: Risk of non-convulsive status epilepticus (see Comment).",
    "Cefepime can competitively inhibit the major CNS inhibitory neurotransmitter, GABA.",
    "Toxicity is concentration dependent.",
    "Impaired renal function is risk factor.",
    "Manifestations can include any or all of: confusion, loss of attention, disorientation, abnormal behavior, agitation, hallucinations, myoclonic jerks, mutism, impaired consciousness, coma.",
    "Diagnosis: EEG.",
    "Review: J Antimicrob Chemother 2022;77: 2908."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Citrobacter freundii",
        "Citrobacter koseri, diversus",
        "Pseudomonas aeruginosa"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "164 (2 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "20",
    "volume_of_distribution_vd_l_vss": "18 L (Vss)",
    "avg_serum_half_life_hr": "2",
    "elimination": "Renal",
    "bile_penetration_percent": "10-20",
    "csf_blood_percent": "4-34 16",
    "therapeutic_levels_in_csf": "Yes",
    "auc_ug_hr_ml": "284.8 (2 gm IV, 0-inf)"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ],
  "comments": [
      "In a June 2012 FDA safety update, clinicians are warned about nonconvulsive status epilepticus occurring in cefepime-treated patients with renal insufficiency, most of whom did not receive appropriately adjusted doses. Seizure activity resolved after drug discontinuation and/or hemodialysis in the majority of patients. The FDA recommends dose adjustment in patients with CrCl ≤ 60 mL/min."
  ]
}
